普拉克索联合奥氮平治疗帕金森伴精神障碍性疾病的临床应用效果观察

Observation on Clinical Application Effect of Pramipexole Combined with Olanzapine in the Treatment of Parkinson’s Disease Accompanying with Mental Disorders

目的:研究普拉克索联合奥氮平治疗帕金森伴精神障碍性疾病的临床效果。方法:选择2016年1月—2018年5月我院收治的120例帕金森伴精神障碍性疾病患者,根据随机数字表法分为观察组和对照组,各60例。对照组采用普拉克索片(0.25 mg,tid)治疗,观察组在此基础上联合奥氮平片(10 mg,bid)治疗。比较两组临床疗效,及帕金森病调查问卷(PDQ-39)评分、汉密尔顿抑郁量表(HAMD)评分、不良反应发生率情况。结果:观察组临床总有效率高于对照组,差异有统计学意义(P<0.05);治疗后两组PDQ-39、HAMD评分均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:普拉克索联合奥氮平治疗帕金森伴精神障碍性疾病的临床效果显著,能进一步改善患者的帕金森病症状和精神抑郁症状,且安全性好,有较高的临床应用价值。

Objective:To study the clinical effect of pramipexole combined with olanzapine in the treatment of Parkinson’s disease accompanying with mental disorders.Methods:120 patients with Parkinson’s disease accompanying with mental disorders admitted to our hospital from January 2016 to May 2018 were selected and randomly divided into an observation group and a control group,60 cases each.The patients in the control group were treated with pramipexole tablets(0.25 mg,tid),and the patients in the observation group were treated with olanzapine tablets(10 mg,bid).The clinical efficacy,Parkinson’s disease questionnaire(PDQ-39)score,Hamilton depression rating scale(HAMD)score and the incidence of adverse reactions were compared between the two groups.Results:The total clinical effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The PDQ-39 and HAMD scores after treatment were lower than those before treatment in the two groups,and the scores in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Pramipexole combined with olanzapine is significantly effective in the treatment of Parkinson’s disease accompanying with mental disorders,which can further improve the symptoms of Parkinson’s disease and mental depression,and has good safety and a high clinical value.